pb101
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2018 (NCT07271446)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vascular endothelial growth factor CINHIBITOR
VEGFC inhibitor
inhibitor - pigf
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06075849 | Phase 1 | Oct 25, 2023 | Catholic University of Korea, CHA University, Panolos Bioscience, Seoul National University |
| NCT07271446 | Phase 1 | Sep 1, 2018 | Chongqing Precision Biotech Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2023 |
| CHA University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Chongqing Precision Biotech Co., Ltd | For profit | 1 | 1 | 1 | 2018 |
| Panolos Bioscience | For profit | 1 | 1 | 1 | 2023 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1